Targeted Delivery Platforms for the Treatment of Multiple Sclerosis

Mol Pharm. 2022 Jul 4;19(7):1952-1976. doi: 10.1021/acs.molpharmaceut.1c00892. Epub 2022 May 2.

Abstract

Multiple sclerosis (MS) is a neurodegenerative condition of the central nervous system (CNS) that presents with varying levels of disability in patients, displaying the significance of timely and effective management of this complication. Though several treatments have been developed to protect nerves, comprehensive improvement of MS is still considered an essential bottleneck. Therefore, the development of innovative treatment methods for MS is one of the core research areas. In this regard, nanoscale platforms can offer practical and ideal approaches to the diagnosis and treatment of various diseases, especially immunological disorders such as MS, to improve the effectiveness of conventional therapies. It should be noted that there is significant progress in the development of neuroprotective strategies through the implementation of various nanoparticles, monoclonal antibodies, peptides, and aptamers. In this study, we summarize different particle systems as well as targeted therapies, such as antibodies, peptides, nucleic acids, and engineered cells for the treatment of MS, and discuss their potential in the treatment of MS in the preclinical and clinical stages. Future advances in targeted delivery of medical supplies may offer new strategies for complete recovery as well as practical treatment of progressive forms of MS.

Keywords: central nervous system; multiple sclerosis; nanomedicine; nanoparticles; targeted delivery platforms.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal / therapeutic use
  • Drug Delivery Systems
  • Humans
  • Multiple Sclerosis* / drug therapy
  • Nanoparticles*
  • Peptides / therapeutic use

Substances

  • Antibodies, Monoclonal
  • Peptides